References
- Wright RS, Anderson JL, Adams CD et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 57(19), 1920–1959 (2011).
- Eisenberg MJ, Richard PR, Libersan D, Filion KB. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 119(12), 1634–1642 (2009).
- Ho PM, Peterson ED, Wang L et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 299(5), 532–539 (2008).
- Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494–502 (2001).
- Steinhubl SR, Berger PB, Mann JT 3rd et al.; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288(19), 2411–2420 (2002).
- Wiviott SD, Braunwald E, McCabe CH et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001–2015 (2007).
- Wallentin L, Becker RC, Budaj A et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045–1057 (2009).
- Angiolillo DJ, Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am. Heart J. 156(Suppl. 2), S10–S15 (2008).
- Greenbaum AB, Grines CL, Bittl JA et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, Phase II, multicenter, randomized, placebo- and active-controlled trial. Am. Heart J. 151(3), 689.e1–689.e10 (2006).
- Bhatt DL, Lincoff AM, Gibson CM et al.; CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med. 361(24), 2330–2341 (2009).
- Harrington RA, Stone GW, McNulty S et al. Platelet inhibition with cangrelor in patients undergoing PCI. N. Engl. J. Med. 361(24), 2318–2329 (2009).
- Bhatt DL, Stone GW, Mahaffey KW et al.; CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N. Engl. J. Med. 368(14), 1303–1313 (2013).
- Angiolillo DJ, Firstenberg MS, Price MJ et al.; BRIDGE Investigators. Bridging Antiplatelet Therapy with Cangrelor in Patients Undergoing Cardiac Surgery: a randomized controlled trial. JAMA 307(3), 265–274 (2012).
- Grines CL, Bonow RO, Casey DE Jr et al.; American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115(6), 813–818 (2007).
- Chassot PG, Delabays A, Spahn DR. Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br. J. Anaesth. 99(3), 316–328 (2007).